Pregled bibliografske jedinice broj: 1268663
Continuous Glucose Monitoring and Type 1 Diabetes Mellitus Control in Child, Adolescent and Young Adult Population – Arguments for Its Use and Effects
Continuous Glucose Monitoring and Type 1 Diabetes Mellitus Control in Child, Adolescent and Young Adult Population – Arguments for Its Use and Effects // Acta clinica Croatica, 60 (2021), 4; 609-616 doi:10.20471/acc.2021.60.04.07 (domaća recenzija, članak, znanstveni)
CROSBI ID: 1268663 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Continuous Glucose Monitoring and Type 1 Diabetes
Mellitus Control in Child, Adolescent and Young
Adult Population – Arguments for Its Use and
Effects
(Continuous Glucose Monitoring and Type 1 Diabetes
Mellitus Control in Child, Adolescent and Young Adult
Population – Arguments for Its Use and Effects)
Autori
Rubelj, Karla ; Stipančić, Gordana ; La Grasta Sabolić, Lavinia ; Požgaj Šepec, Marija
Izvornik
Acta clinica Croatica (0353-9466) 60
(2021), 4;
609-616
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
type 1 diabetes mellitus ; continuous glucose monitoring ; children ; adolescents
Sažetak
Sensors for continuous glucose monitoring (CGM) in intercellular fluid are usedas a contemporary method to achieve better control in type 1 diabetes mellitus (DM), which is best shown through lower glycated hemoglobin (HbA1c) levels.The aim of this study was to assess how many of our patients used CGM (parents were solely financing all the cost of the device) and what was the effect of CGM on the control of DM. Data were retrospectively collected from medical records of patients actively treated at the Division of Endocrinology, Diabetology, Pulmonology and Allergology, Department of Pediatrics, Sestre milosrdnice University Hospital Center. The t-test was used for independent samples to compare the mean levels of HbA1c before and after the inclusion of CGM. CGM was used by 81 (32.1%) of our patients with type 1 DM, of which 43 met the inclusion criteria. The mean HbA1c level 6 months before the introduction of CGM was 8.2%±1.9 and after 12 monthsof CGM use it was 7.4%±1.2, which was a statistically significant improvement (p=0.026). Furthermore, our results demonstrated that the greatest improvement in HbA1c level was recorded in thegroups of young adults (18-25 years) and youngest children (<12 years). We confirmed the efficacy ofCGM in achieving better control of type 1 DM by significantly improving HbA1c levels in a population of highly motivated patients.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Stomatološki fakultet, Zagreb,
KBC "Sestre Milosrdnice"
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE